Zenagamtide

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

ObesityType 2 Diabetes

190 competitors in Obesity

#DrugCompanyPhaseTrials

1

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 3

12

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

13

NNC0487-0111

Novo Nordisk

Phase 3

114

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

15

Eloralintide

Eli Lilly

Phase 3

106

Ribupatide

KKailera

Phase 3

37

Elecoglipron

AstraZeneca

Phase 3

18

Belantamab Mafodotin-Blmf

Novo Nordisk

Phase 3

19

PF-08653944

Pfizer

Phase 3

510

Zenagamtide

Novo Nordisk

Phase 3

3Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Obesity3 trials

Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)

Not yet recruiting·Novo Nordisk·Phase 3·NCT07668414·650 enrolled

Efficacy and Safety of Once-daily Oral Zenagamtide in Participants With Obesity (AMAZE 9)

Not yet recruiting·Novo Nordisk·Phase 3·NCT07720271·950 enrolled

Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)

Not yet recruiting·Novo Nordisk·Phase 3·NCT07668401·400 enrolled

Type 2 Diabetes1 trial

Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Insulin Glargine s.c. Once Daily in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Inadequately Controlled on 1-3 Oral Glucose-lowering Medications (AMBITION 7)

Recruiting·Novo Nordisk·Phase 3·NCT07797335·1,778 enrolled

Details

Drug Info

Related News